Table 4.
Differences in enrollment between patients with FIB-4 > 1.3 and FIB-4 ≤ 1.3.
| Variables | Patients with FIB-4 > 1.3 (n = 59, 28.2%) |
Patients with FIB-4 ≤ 1.3 (n = 150, 71.8%) |
p Value |
|---|---|---|---|
| Sex (M/F) | 49/10 (83%/17%) | 103/47 (68.7%/31.3%) | 0.039 |
| Age (years) | 71 (14) 70.2 ± 9.3 |
64 (14) 62.5 ± 10.9 |
<0.001 |
| Weight (Kg) | 87 (16.5) 88.6 ± 13 |
85 (30) 90.5 ± 21.5 |
0.712 |
| BMI (Kg/m2) | 28.4 (8.60 30 ± 4.9 |
29.4 (8.4) 30.7 ± 6.1 |
0.683 |
| HbA1c (%) | 6.6 (1.6) 7 ± 1.3 |
7.4 (2.5) 8 ± 2.1 |
<0.001 |
| LDL (mg/dL) | 71.5 (44.3) 81 ± 5 |
97 (55) 100.7 ± 40.7 |
0.003 |
| HDL (mg/dL) | 45 (14) 45.6 ± 10.3 |
43 (16) 44.2 ± 11.3 |
0.402 |
| Tg (mg/dL) | 119.5 (101) 157.9 ± 107.1 |
158 (102) 189.2 ± 131 |
<0.001 |
| Metformin | 33 (55.9%) | 120 (80%) | <0.001 |
| DPP-4 inhibitors | 16 (27.1%) | 31 (20.7%) | 0.358 |
| SGLT-2 inhibitors | 25 (42.4%) | 39 (26%) | 0.03 |
| GLP-1 analogs | 18 (30.5%) | 51 (34%) | 0.744 |
| Sulfonylureas | 6 (10.2%) | 16 (10.7%) | 0.916 |
| Pioglitazone | 1 (1.7%) | 6 (4%) | 0.676 |
| Insulin | 24 (40.7%) | 55 (36.7%) | 0.636 |
| Hypertension | 31 (52.5%) | 65 (43.3%) | 0.281 |
Variables are expressed as median value and interquartile range (IQR) or number of cases (percentages). (Mean value ± standard deviation (SD) is presented underneath.) M/F: male/female; BMI: body mass index; HbA1c: glycated hemoglobulin A1; LDL: low-density lipoprotein; HDL: high-density lipoprotein; Tg: triglycerides; DPP-4: dipeptidyl peptidase-4; SGLT-2: Sodium-Glucose Transport Protein-2; GLP-1: glucagon-like peptide-1. The table displays patients’ lipid values and antidiabetic treatment at the study's enrollment time.